Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma
Shots:
- Alcon is removing CyPass globally revealing its unmet needs with safety of patients with the guidance for surgeons to stop its further use and return the fresh devices
- The above decision is on the basis of five-year data from COMPASS-XT long-term safety study
- The study showed reduction in intraocular pressure at two yrs- resulting a little difference in endothelial cell loss and at five yrs experienced reduction in endothelial cell loss vs cataract surgery alone
- Sukamenak
Ref: Novartis | Image: Novartis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
